Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

P Moreau; SK Kumar; J San Miguel; F Davies; E Zamagni; N Bahlis; H Ludwig; J Mikhael; E Terpos; F Schjesvold; T Martin; K Yong; BGM Durie; T Facon; A Jurczyszyn; S Sidana; N Raje; N van de Donk; S Lonial; M Cavo; SY Kristinsson; S Lentzsch; R Hajek; KC Anderson; C João; H Einsele; Pieter Sonneveld; M Engelhardt; R Fonseca; A Vangsted; K Weisel; R Baz; V Hungria; JG Berdeja; F (Frederico) Costa; A Maiolino; A Waage; DH Vesole; EM Ocio; H Quach; C Driessen; J Bladé; X Leleu; E Riva; PL Bergsagel; J Hou; WJ Chng; UH Mellqvist; D Dytfeld; JL Harousseau; H Goldschmidt; J Laubach; NC Munshi; F Gay; M Beksac; LJ Costa; M Kaiser; P Hari; M Boccadoro; S Z Usmani; S Zweegman; S Holstein; O Sezer; S Harrison; H Nahi; G Cook; MV Mateos; SV Rajkumar; MA Dimopoulos; PG Richardson

doi:10.1016/S1470-2045(20)30756-7

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

P Moreau
, SK Kumar
, J San Miguel
, F Davies
, E Zamagni
, N Bahlis
, H Ludwig
, J Mikhael
, E Terpos
, F Schjesvold
, T Martin
, K Yong
, BGM Durie
, T Facon
, A Jurczyszyn
, S Sidana
, N Raje
, N van de Donk
, S Lonial
, M Cavo

SY Kristinsson, S Lentzsch, R Hajek, KC Anderson, C João, H Einsele, Pieter Sonneveld, M Engelhardt, R Fonseca, A Vangsted, K Weisel, R Baz, V Hungria, JG Berdeja, F (Frederico) Costa, A Maiolino, A Waage, DH Vesole, EM Ocio, H Quach, C Driessen, J Bladé, X Leleu, E Riva, PL Bergsagel, J Hou, WJ Chng, UH Mellqvist, D Dytfeld, JL Harousseau, H Goldschmidt, J Laubach, NC Munshi, F Gay, M Beksac, LJ Costa, M Kaiser, P Hari, M Boccadoro, S Z Usmani, S Zweegman, S Holstein, O Sezer, S Harrison, H Nahi, G Cook, MV Mateos, SV Rajkumar, MA Dimopoulos, PG Richardson

Hematology

External organisation

Research output: Contribution to journal › Article › Academic › peer-review

234 Citations (Scopus)

Abstract

This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes.

Original language	English
Pages (from-to)	e105-e118
Journal	The Lancet Oncology
Volume	22
Issue number	3
DOIs	https://doi.org/10.1016/S1470-2045(20)30756-7
Publication status	Published - Mar 2021

Bibliographical note

Funding Information:
PM reports honoraria from Amgen, Celgene, Janssen, AbbVie, and Sanofi; and participation in advisory boards for Amgen, Celgene, Janssen, AbbVie, and Sanofi. SKK reports research grants from AbbVie, Celgene, Janssen, Takeda, Adaptive, Kite, Medimmune (AstraZeneca), Merck Sharp and Dohme, Novartis, Roche, Sanofi, and Oncopeptides; and participation in the advisory boards of and research support for clinical trials paid to institution from AbbVie, Celgene, Janssen, Takeda, Adaptive, Kite, Medimmune (AstraZeneca), and Oncopeptides. JSM reports participation in advisory boards for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Merck Sharp and Dohme, Novartis, Takeda, Roche, Sanofi, GlaxoSmithKline, AbbVie, and Karyopharm. FD reports research grants from Janssen and Celgene; honoraria from Adaptive Biotech, Janssen, Celgene, Takeda, Sanofi, Oncopeptide, and Roche; and participation in advisory boards for Adaptive Biotech, Janssen, Celgene, Takeda, Sanofi, Oncopeptide, and Roche. NB reports research grants from Celgene; and honoraria from Janssen, AbbVie, Sanofi, Genentech, Amgen, Karyopharm, and Pfizer. HL reports research funding from Takeda and Amgen; and honoraria from Takeda, Amgen, Sanofi, Janssen, and Celgene. JM reports honoraria from Amgen, Bristol-Myers Squibb, Janssen, Karyopharm, Sanofi, and Takeda. ET reports research grants from Janssen, Amgen, Celgene, Genesis Pharma, and Sanofi; honoraria from Janssen, Takeda, Amgen, Celgene, Genesis Pharma, Sanofi, Bristol-Myers Squibb, and Novartis; and non-financial support from Takeda, Amgen, Celgene, and Genesis Pharma. FS reports research grants from Amgen, Celgene, Oncopeptides, Sanofi, and GlaxoSmithKline; and honoraria from Amgen, Celgene, Takeda, Janssen, Novartis, SlyliteDX, Oncopeptides, Sanofi, GlaxoSmithKline, and Merck Sharp and Dohme. TM reports research support paid to institution from Sanofi, Amgen, Janssen, and Seattle Genetics; and consulting for Roche and GlaxoSmithKline. KY reports research grants from Sanofi and Janssen; and honoraria from Takeda. TF reports honoraria from Janssen, Bristol-Myers Squibb, Takeda, Amgen, Sanofi, Roche, Oncopeptides, and Karyopharm. SS reports research grants from Magenta Therapeutics and honoraria from Janssen. NR reports research grants from Blue Bird Bio; and honoraria from Bristol-Myers Squibb, Amgen, Janssen, Takeda, AstraZeneca, Oncopeptide, Immuneel, and Caribou Biosciences. NvdD reports research grants from Janssen Pharmaceuticals, Amgen, Celgene, Novartis, and Bristol-Myers Squibb. SLo reports honoraria from Celgene, Bristol-Myers Squibb, Janssen, Takeda, Novartis, GlaxoSmithKline, AbbVie, and Karyopharm. MC reports honoraria from Janssen, Celgene, Bristol-Myers Squibb, Sanofi, GlaxoSmithKline, and Mundipharma. SLe reports research grants from Sanofi and Karyopharm; and honoraria from Sorrento, Janssen, Cellularity, Caelum, Takeda, Adaptive, GlaxoSmithKline, Sanofi, AbbVie, Bayer, Amgen, and Proclara. RH reports research grants from Takeda and Novartis; and honoraria from Janssen, Amgen, Celgene, AbbVie, Bristol-Myers Squibb, Pharmamar, Takeda, and Novartis. KCA reports honoraria from Bristol-Myers Squibb, Millenium Pharmaceuticals, Gilead, Sanofi, Amgen, and Precision Biosciences; and is a scientific founder of C4 therapeutics and Oncopep. CJ reports research grants from Takeda; and honoraria from Takeda, Janssen, Celgene, and Amgen. HE reports research grants from Celgene, Janssen, Amgen, Sanofi, and GlaxoSmithKline; and honoraria from Celgene, Janssen, Amgen, Takeda, Sanofi, and GlaxoSmithKline. PS reports research grants from Amgen, Celgene, Janssen, Karyopharm, SkylineDX, and Takeda; and honoraria from Amgen, Celgene, Janssen, Karyopharm, SkylineDX, and Takeda. ME reports research grants from Amgen, Janssen, Takeda, and Bristol-Myers Squibb. RF reports being a consultant for Merck Sharp and Dohme, Novartis, Oncotracker, Pharmacyclics, GlaxoSmithKline, Janssen, Sanofi, Takeda, and Oncopeptides; and has a FISH patent with royalties paid. KW reports research grants from Amgen, Celgene, Janssen, and Sanofi; and honoraria from Amgen, Celgene, Bristol-Myers Squibb, Adaptive Biotech, Janssen, GlaxoSmithKline, Karyopharm, Sanofi, Takeda, and Oncopeptides. RB reports research grants from Janssen, Bristol-Myers Squibb, Karyopharm, Sanofi, and AbbVie; and honoraria from Janssen, Celgene, Karyopharm, Sanofi, and GlaxoSmithKline. VH reports honoraria from AbbVie, Amgen, Bristol-Myers Squibb, Janssen, Sanofi, and Takeda. JGB reports research grants from Vivolux, AbbVie, Amgen, Acetylon, Bluebird, Bristol-Myers Squibb, Celgene, Cellularity, Constellation, CRISPR Therapeutics, CURIS, EMD Sorono, GenentechInc, Glenmark, Janssen, Kesios, Lilly, Novartis, Poseida, Teva, and Takeda; and being a consultant for Amgen, Bioclinica, Bristol-Myers Squibb, Celgene, CRISPR Therapeutics, Janssen, Karyopharm, Kite Pharma, Legend, Prothena, Servier, Takeda, Bluebird, and SecuraBio. FLdC reports honoraria from Amgen, Takeda, Janssen, Viforpharma, and Celgene. AM reports honoraria from Janssen, Takeda, Amgen, Bristol-Myers Squibb, and Sanofi. AW reports research grants from Takeda and honoraria from Janssen. DHV reports honoraria from Amgen, Takeda, Janssen, GlaxoSmithKline, Karyopharm, and Bristol-Myers Squibb. EMO reports honoraria from Celgene, Janssen, Sanofi, Amgen, Merck Sharp and Dohme, Asofarma, Takeda, SecuraBio, Oncopeptides, and GlaxoSmithKline. HQ reports research grants from GlaxoSmithKline, Amgen, Karyopharm, and Celgene; and honoraria from GlaxoSmithKline, Amgen, and Karyopharm. JB reports honoraria from Janssen, Celgene, Amgen, Takeda, and Oncopeptides. PLB reports honoraria from Celgene, Janssen, GlaxoSmithKline, and Novartis. JH reports research grants from the National Natural Science Foundation of China and honoraria from Janssen. U-HM reports honoraria from Janssen, Sanofi, Amgen, Celgene, and Oncopeptides. DD reports research grants from Celgene and Janssen; and honoraria from Amgen, Celgene, Janssen, and Takeda. J-LH reports honoraria from GlaxoSmithKline, Daichi, and Janssen. HG reports research grants from Bristol-Myers Squibb, Celgene, Janssen, Chugai, Sanofi, Takeda, Novartis, Incyte, Molecular Partners, Mundipharma, and Adaptive Technologies; and honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Chugai, Sanofi, Novartis, and GlaxoSmithKline. NCM reports honoraria from AbbVie, Adaptive, Amgen, BeiGene, Bristol-Myers Squibb, Celgene, Janssen, Karyopharm, Takeda, and Oncopep. FG reports honoraria from Amgen, Celgene, Janssen, Takeda, Bristol-Myers Squibb, Roche, AbbVie, Adaptive Biotechnologies, Seattle Genetics, Oncopeptides, and GlaxoSmithKline. MBe reports participation in advisory boards for Amgen, Bristol-Myers Squibb, Janssen, Sanofi, Takeda, and Oncopeptides. LJC reports research grants from Amgen and Janssen; and honoraria from Amgen, Janssen, Genentech, AstraZeneca, and Bristol-Myers Squibb. MK reports research grants from Janssen and honoraria from Amgen, AbbVie, Celgene, GlaxoSmithKline, Janssen, Karyopharm, and Takeda. PH reports research grants from Celgene, Takeda, Janssen, GlaxoSmithKline, and Sanofi; and honoraria from Celgene, Takeda, Amgen, Karyopharm, Janssen, GlaxoSmithKline, and Sanofi. MBo reports research grants from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and Mundipharma; and honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, AbbVie, and GlaxoSmithKline. SZU reports research grants from Amgen, Bristol-Myers Squibb, Celgene, Pharmacyclics, Sanofi, Seattle Genetics, Janssen, Takeda, SkylineDX, and Merck Sharp and Dohme; and honoraria from Amgen, AbbVie, Celgene, Mundipharma, Sanofi, Seattle Genetics, Janssen, Takeda, SkylineDX, and Merck Sharp and Dohme. SZ reports research grants from Janssen and Takeda; and being a consultant for Janssen, Takeda, Bristol-Myers Squibb, Sanofi, and Oncopeptides. SHo reports research grants from Oncopeptides; and honoraria from Celgene, GlaxoSmithKline, Oncopeptides, Sorrento, Sanofi, Genentech, and Takeda. SHa reports research grants from Bristol-Myers Squib, Celgene, Janssen, and Amgen; and honoraria from Bristol-Myers Squib, Celgene, Janssen, Amgen, Takeda, GlaxoSmithKline, AbbVie, and Karyopharm. GC reports research grants from Takeda, Celgene, and Janssen; and honoraria from Takeda, Celgene, Janssen, and Karyopharm. M-VM reports honoraria from Janssen, Bristol-Myers Squib, Amgen, Takeda, GlaxoSmithKline, AbbVie, Adaptive, Pfizer, Genentech, Roche, Oncopeptides, and Sanofi. MAD reports honoraria from Amgen, Bristol-Myers Squib, Janssen, Takeda, and Beigene. PGR reports research grants from Bristol-Myers Squib, Oncopeptides, Celgene, Takeda; and honoraria from Oncopeptides, Celgene, Takeda, Karyopharm, Janssen, Sanofi, and SecuraBio. All other authors declare no competing interests.

Publisher Copyright:
© 2021 Elsevier Ltd

Research programs

EMC OR-01

Access to Document

10.1016/S1470-2045(20)30756-7

Cite this

Moreau, P., Kumar, SK., San Miguel, J., Davies, F., Zamagni, E., Bahlis, N., Ludwig, H., Mikhael, J., Terpos, E., Schjesvold, F., Martin, T., Yong, K., Durie, BGM., Facon, T., Jurczyszyn, A., Sidana, S., Raje, N., van de Donk, N., Lonial, S., ... Richardson, PG. (2021). Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. The Lancet Oncology, 22(3), e105-e118. https://doi.org/10.1016/S1470-2045(20)30756-7

@article{3d7e88950b01463db42b547e2e72e65e,

title = "Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group",

abstract = "This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes.",

author = "P Moreau and SK Kumar and \{San Miguel\}, J and F Davies and E Zamagni and N Bahlis and H Ludwig and J Mikhael and E Terpos and F Schjesvold and T Martin and K Yong and BGM Durie and T Facon and A Jurczyszyn and S Sidana and N Raje and \{van de Donk\}, N and S Lonial and M Cavo and SY Kristinsson and S Lentzsch and R Hajek and KC Anderson and C Jo{\~a}o and H Einsele and Pieter Sonneveld and M Engelhardt and R Fonseca and A Vangsted and K Weisel and R Baz and V Hungria and JG Berdeja and Costa, \{F (Frederico)\} and A Maiolino and A Waage and DH Vesole and EM Ocio and H Quach and C Driessen and J Blad{\'e} and X Leleu and E Riva and PL Bergsagel and J Hou and WJ Chng and UH Mellqvist and D Dytfeld and JL Harousseau and H Goldschmidt and J Laubach and NC Munshi and F Gay and M Beksac and LJ Costa and M Kaiser and P Hari and M Boccadoro and Usmani, \{S Z\} and S Zweegman and S Holstein and O Sezer and S Harrison and H Nahi and G Cook and MV Mateos and SV Rajkumar and MA Dimopoulos and PG Richardson",

note = "Funding Information: PM reports honoraria from Amgen, Celgene, Janssen, AbbVie, and Sanofi; and participation in advisory boards for Amgen, Celgene, Janssen, AbbVie, and Sanofi. SKK reports research grants from AbbVie, Celgene, Janssen, Takeda, Adaptive, Kite, Medimmune (AstraZeneca), Merck Sharp and Dohme, Novartis, Roche, Sanofi, and Oncopeptides; and participation in the advisory boards of and research support for clinical trials paid to institution from AbbVie, Celgene, Janssen, Takeda, Adaptive, Kite, Medimmune (AstraZeneca), and Oncopeptides. JSM reports participation in advisory boards for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Merck Sharp and Dohme, Novartis, Takeda, Roche, Sanofi, GlaxoSmithKline, AbbVie, and Karyopharm. FD reports research grants from Janssen and Celgene; honoraria from Adaptive Biotech, Janssen, Celgene, Takeda, Sanofi, Oncopeptide, and Roche; and participation in advisory boards for Adaptive Biotech, Janssen, Celgene, Takeda, Sanofi, Oncopeptide, and Roche. NB reports research grants from Celgene; and honoraria from Janssen, AbbVie, Sanofi, Genentech, Amgen, Karyopharm, and Pfizer. HL reports research funding from Takeda and Amgen; and honoraria from Takeda, Amgen, Sanofi, Janssen, and Celgene. JM reports honoraria from Amgen, Bristol-Myers Squibb, Janssen, Karyopharm, Sanofi, and Takeda. ET reports research grants from Janssen, Amgen, Celgene, Genesis Pharma, and Sanofi; honoraria from Janssen, Takeda, Amgen, Celgene, Genesis Pharma, Sanofi, Bristol-Myers Squibb, and Novartis; and non-financial support from Takeda, Amgen, Celgene, and Genesis Pharma. FS reports research grants from Amgen, Celgene, Oncopeptides, Sanofi, and GlaxoSmithKline; and honoraria from Amgen, Celgene, Takeda, Janssen, Novartis, SlyliteDX, Oncopeptides, Sanofi, GlaxoSmithKline, and Merck Sharp and Dohme. TM reports research support paid to institution from Sanofi, Amgen, Janssen, and Seattle Genetics; and consulting for Roche and GlaxoSmithKline. KY reports research grants from Sanofi and Janssen; and honoraria from Takeda. TF reports honoraria from Janssen, Bristol-Myers Squibb, Takeda, Amgen, Sanofi, Roche, Oncopeptides, and Karyopharm. SS reports research grants from Magenta Therapeutics and honoraria from Janssen. NR reports research grants from Blue Bird Bio; and honoraria from Bristol-Myers Squibb, Amgen, Janssen, Takeda, AstraZeneca, Oncopeptide, Immuneel, and Caribou Biosciences. NvdD reports research grants from Janssen Pharmaceuticals, Amgen, Celgene, Novartis, and Bristol-Myers Squibb. SLo reports honoraria from Celgene, Bristol-Myers Squibb, Janssen, Takeda, Novartis, GlaxoSmithKline, AbbVie, and Karyopharm. MC reports honoraria from Janssen, Celgene, Bristol-Myers Squibb, Sanofi, GlaxoSmithKline, and Mundipharma. SLe reports research grants from Sanofi and Karyopharm; and honoraria from Sorrento, Janssen, Cellularity, Caelum, Takeda, Adaptive, GlaxoSmithKline, Sanofi, AbbVie, Bayer, Amgen, and Proclara. RH reports research grants from Takeda and Novartis; and honoraria from Janssen, Amgen, Celgene, AbbVie, Bristol-Myers Squibb, Pharmamar, Takeda, and Novartis. KCA reports honoraria from Bristol-Myers Squibb, Millenium Pharmaceuticals, Gilead, Sanofi, Amgen, and Precision Biosciences; and is a scientific founder of C4 therapeutics and Oncopep. CJ reports research grants from Takeda; and honoraria from Takeda, Janssen, Celgene, and Amgen. HE reports research grants from Celgene, Janssen, Amgen, Sanofi, and GlaxoSmithKline; and honoraria from Celgene, Janssen, Amgen, Takeda, Sanofi, and GlaxoSmithKline. PS reports research grants from Amgen, Celgene, Janssen, Karyopharm, SkylineDX, and Takeda; and honoraria from Amgen, Celgene, Janssen, Karyopharm, SkylineDX, and Takeda. ME reports research grants from Amgen, Janssen, Takeda, and Bristol-Myers Squibb. RF reports being a consultant for Merck Sharp and Dohme, Novartis, Oncotracker, Pharmacyclics, GlaxoSmithKline, Janssen, Sanofi, Takeda, and Oncopeptides; and has a FISH patent with royalties paid. KW reports research grants from Amgen, Celgene, Janssen, and Sanofi; and honoraria from Amgen, Celgene, Bristol-Myers Squibb, Adaptive Biotech, Janssen, GlaxoSmithKline, Karyopharm, Sanofi, Takeda, and Oncopeptides. RB reports research grants from Janssen, Bristol-Myers Squibb, Karyopharm, Sanofi, and AbbVie; and honoraria from Janssen, Celgene, Karyopharm, Sanofi, and GlaxoSmithKline. VH reports honoraria from AbbVie, Amgen, Bristol-Myers Squibb, Janssen, Sanofi, and Takeda. JGB reports research grants from Vivolux, AbbVie, Amgen, Acetylon, Bluebird, Bristol-Myers Squibb, Celgene, Cellularity, Constellation, CRISPR Therapeutics, CURIS, EMD Sorono, GenentechInc, Glenmark, Janssen, Kesios, Lilly, Novartis, Poseida, Teva, and Takeda; and being a consultant for Amgen, Bioclinica, Bristol-Myers Squibb, Celgene, CRISPR Therapeutics, Janssen, Karyopharm, Kite Pharma, Legend, Prothena, Servier, Takeda, Bluebird, and SecuraBio. FLdC reports honoraria from Amgen, Takeda, Janssen, Viforpharma, and Celgene. AM reports honoraria from Janssen, Takeda, Amgen, Bristol-Myers Squibb, and Sanofi. AW reports research grants from Takeda and honoraria from Janssen. DHV reports honoraria from Amgen, Takeda, Janssen, GlaxoSmithKline, Karyopharm, and Bristol-Myers Squibb. EMO reports honoraria from Celgene, Janssen, Sanofi, Amgen, Merck Sharp and Dohme, Asofarma, Takeda, SecuraBio, Oncopeptides, and GlaxoSmithKline. HQ reports research grants from GlaxoSmithKline, Amgen, Karyopharm, and Celgene; and honoraria from GlaxoSmithKline, Amgen, and Karyopharm. JB reports honoraria from Janssen, Celgene, Amgen, Takeda, and Oncopeptides. PLB reports honoraria from Celgene, Janssen, GlaxoSmithKline, and Novartis. JH reports research grants from the National Natural Science Foundation of China and honoraria from Janssen. U-HM reports honoraria from Janssen, Sanofi, Amgen, Celgene, and Oncopeptides. DD reports research grants from Celgene and Janssen; and honoraria from Amgen, Celgene, Janssen, and Takeda. J-LH reports honoraria from GlaxoSmithKline, Daichi, and Janssen. HG reports research grants from Bristol-Myers Squibb, Celgene, Janssen, Chugai, Sanofi, Takeda, Novartis, Incyte, Molecular Partners, Mundipharma, and Adaptive Technologies; and honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Chugai, Sanofi, Novartis, and GlaxoSmithKline. NCM reports honoraria from AbbVie, Adaptive, Amgen, BeiGene, Bristol-Myers Squibb, Celgene, Janssen, Karyopharm, Takeda, and Oncopep. FG reports honoraria from Amgen, Celgene, Janssen, Takeda, Bristol-Myers Squibb, Roche, AbbVie, Adaptive Biotechnologies, Seattle Genetics, Oncopeptides, and GlaxoSmithKline. MBe reports participation in advisory boards for Amgen, Bristol-Myers Squibb, Janssen, Sanofi, Takeda, and Oncopeptides. LJC reports research grants from Amgen and Janssen; and honoraria from Amgen, Janssen, Genentech, AstraZeneca, and Bristol-Myers Squibb. MK reports research grants from Janssen and honoraria from Amgen, AbbVie, Celgene, GlaxoSmithKline, Janssen, Karyopharm, and Takeda. PH reports research grants from Celgene, Takeda, Janssen, GlaxoSmithKline, and Sanofi; and honoraria from Celgene, Takeda, Amgen, Karyopharm, Janssen, GlaxoSmithKline, and Sanofi. MBo reports research grants from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and Mundipharma; and honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, AbbVie, and GlaxoSmithKline. SZU reports research grants from Amgen, Bristol-Myers Squibb, Celgene, Pharmacyclics, Sanofi, Seattle Genetics, Janssen, Takeda, SkylineDX, and Merck Sharp and Dohme; and honoraria from Amgen, AbbVie, Celgene, Mundipharma, Sanofi, Seattle Genetics, Janssen, Takeda, SkylineDX, and Merck Sharp and Dohme. SZ reports research grants from Janssen and Takeda; and being a consultant for Janssen, Takeda, Bristol-Myers Squibb, Sanofi, and Oncopeptides. SHo reports research grants from Oncopeptides; and honoraria from Celgene, GlaxoSmithKline, Oncopeptides, Sorrento, Sanofi, Genentech, and Takeda. SHa reports research grants from Bristol-Myers Squib, Celgene, Janssen, and Amgen; and honoraria from Bristol-Myers Squib, Celgene, Janssen, Amgen, Takeda, GlaxoSmithKline, AbbVie, and Karyopharm. GC reports research grants from Takeda, Celgene, and Janssen; and honoraria from Takeda, Celgene, Janssen, and Karyopharm. M-VM reports honoraria from Janssen, Bristol-Myers Squib, Amgen, Takeda, GlaxoSmithKline, AbbVie, Adaptive, Pfizer, Genentech, Roche, Oncopeptides, and Sanofi. MAD reports honoraria from Amgen, Bristol-Myers Squib, Janssen, Takeda, and Beigene. PGR reports research grants from Bristol-Myers Squib, Oncopeptides, Celgene, Takeda; and honoraria from Oncopeptides, Celgene, Takeda, Karyopharm, Janssen, Sanofi, and SecuraBio. All other authors declare no competing interests. Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",

year = "2021",

month = mar,

doi = "10.1016/S1470-2045(20)30756-7",

language = "English",

volume = "22",

pages = "e105--e118",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd.",

number = "3",

}

Moreau, P, Kumar, SK, San Miguel, J, Davies, F, Zamagni, E, Bahlis, N, Ludwig, H, Mikhael, J, Terpos, E, Schjesvold, F, Martin, T, Yong, K, Durie, BGM, Facon, T, Jurczyszyn, A, Sidana, S, Raje, N, van de Donk, N, Lonial, S, Cavo, M, Kristinsson, SY, Lentzsch, S, Hajek, R, Anderson, KC, João, C, Einsele, H, Sonneveld, P, Engelhardt, M, Fonseca, R, Vangsted, A, Weisel, K, Baz, R, Hungria, V, Berdeja, JG, Costa, F, Maiolino, A, Waage, A, Vesole, DH, Ocio, EM, Quach, H, Driessen, C, Bladé, J, Leleu, X, Riva, E, Bergsagel, PL, Hou, J, Chng, WJ, Mellqvist, UH, Dytfeld, D, Harousseau, JL, Goldschmidt, H, Laubach, J, Munshi, NC, Gay, F, Beksac, M, Costa, LJ, Kaiser, M, Hari, P, Boccadoro, M, Usmani, SZ, Zweegman, S, Holstein, S, Sezer, O, Harrison, S, Nahi, H, Cook, G, Mateos, MV, Rajkumar, SV, Dimopoulos, MA & Richardson, PG 2021, 'Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group', The Lancet Oncology, vol. 22, no. 3, pp. e105-e118. https://doi.org/10.1016/S1470-2045(20)30756-7

TY - JOUR

T1 - Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

AU - Moreau, P

AU - Kumar, SK

AU - San Miguel, J

AU - Davies, F

AU - Zamagni, E

AU - Bahlis, N

AU - Ludwig, H

AU - Mikhael, J

AU - Terpos, E

AU - Schjesvold, F

AU - Martin, T

AU - Yong, K

AU - Durie, BGM

AU - Facon, T

AU - Jurczyszyn, A

AU - Sidana, S

AU - Raje, N

AU - van de Donk, N

AU - Lonial, S

AU - Cavo, M

AU - Kristinsson, SY

AU - Lentzsch, S

AU - Hajek, R

AU - Anderson, KC

AU - João, C

AU - Einsele, H

AU - Sonneveld, Pieter

AU - Engelhardt, M

AU - Fonseca, R

AU - Vangsted, A

AU - Weisel, K

AU - Baz, R

AU - Hungria, V

AU - Berdeja, JG

AU - Costa, F (Frederico)

AU - Maiolino, A

AU - Waage, A

AU - Vesole, DH

AU - Ocio, EM

AU - Quach, H

AU - Driessen, C

AU - Bladé, J

AU - Leleu, X

AU - Riva, E

AU - Bergsagel, PL

AU - Hou, J

AU - Chng, WJ

AU - Mellqvist, UH

AU - Dytfeld, D

AU - Harousseau, JL

AU - Goldschmidt, H

AU - Laubach, J

AU - Munshi, NC

AU - Gay, F

AU - Beksac, M

AU - Costa, LJ

AU - Kaiser, M

AU - Hari, P

AU - Boccadoro, M

AU - Usmani, S Z

AU - Zweegman, S

AU - Holstein, S

AU - Sezer, O

AU - Harrison, S

AU - Nahi, H

AU - Cook, G

AU - Mateos, MV

AU - Rajkumar, SV

AU - Dimopoulos, MA

AU - Richardson, PG

N1 - Funding Information: PM reports honoraria from Amgen, Celgene, Janssen, AbbVie, and Sanofi; and participation in advisory boards for Amgen, Celgene, Janssen, AbbVie, and Sanofi. SKK reports research grants from AbbVie, Celgene, Janssen, Takeda, Adaptive, Kite, Medimmune (AstraZeneca), Merck Sharp and Dohme, Novartis, Roche, Sanofi, and Oncopeptides; and participation in the advisory boards of and research support for clinical trials paid to institution from AbbVie, Celgene, Janssen, Takeda, Adaptive, Kite, Medimmune (AstraZeneca), and Oncopeptides. JSM reports participation in advisory boards for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Merck Sharp and Dohme, Novartis, Takeda, Roche, Sanofi, GlaxoSmithKline, AbbVie, and Karyopharm. FD reports research grants from Janssen and Celgene; honoraria from Adaptive Biotech, Janssen, Celgene, Takeda, Sanofi, Oncopeptide, and Roche; and participation in advisory boards for Adaptive Biotech, Janssen, Celgene, Takeda, Sanofi, Oncopeptide, and Roche. NB reports research grants from Celgene; and honoraria from Janssen, AbbVie, Sanofi, Genentech, Amgen, Karyopharm, and Pfizer. HL reports research funding from Takeda and Amgen; and honoraria from Takeda, Amgen, Sanofi, Janssen, and Celgene. JM reports honoraria from Amgen, Bristol-Myers Squibb, Janssen, Karyopharm, Sanofi, and Takeda. ET reports research grants from Janssen, Amgen, Celgene, Genesis Pharma, and Sanofi; honoraria from Janssen, Takeda, Amgen, Celgene, Genesis Pharma, Sanofi, Bristol-Myers Squibb, and Novartis; and non-financial support from Takeda, Amgen, Celgene, and Genesis Pharma. FS reports research grants from Amgen, Celgene, Oncopeptides, Sanofi, and GlaxoSmithKline; and honoraria from Amgen, Celgene, Takeda, Janssen, Novartis, SlyliteDX, Oncopeptides, Sanofi, GlaxoSmithKline, and Merck Sharp and Dohme. TM reports research support paid to institution from Sanofi, Amgen, Janssen, and Seattle Genetics; and consulting for Roche and GlaxoSmithKline. KY reports research grants from Sanofi and Janssen; and honoraria from Takeda. TF reports honoraria from Janssen, Bristol-Myers Squibb, Takeda, Amgen, Sanofi, Roche, Oncopeptides, and Karyopharm. SS reports research grants from Magenta Therapeutics and honoraria from Janssen. NR reports research grants from Blue Bird Bio; and honoraria from Bristol-Myers Squibb, Amgen, Janssen, Takeda, AstraZeneca, Oncopeptide, Immuneel, and Caribou Biosciences. NvdD reports research grants from Janssen Pharmaceuticals, Amgen, Celgene, Novartis, and Bristol-Myers Squibb. SLo reports honoraria from Celgene, Bristol-Myers Squibb, Janssen, Takeda, Novartis, GlaxoSmithKline, AbbVie, and Karyopharm. MC reports honoraria from Janssen, Celgene, Bristol-Myers Squibb, Sanofi, GlaxoSmithKline, and Mundipharma. SLe reports research grants from Sanofi and Karyopharm; and honoraria from Sorrento, Janssen, Cellularity, Caelum, Takeda, Adaptive, GlaxoSmithKline, Sanofi, AbbVie, Bayer, Amgen, and Proclara. RH reports research grants from Takeda and Novartis; and honoraria from Janssen, Amgen, Celgene, AbbVie, Bristol-Myers Squibb, Pharmamar, Takeda, and Novartis. KCA reports honoraria from Bristol-Myers Squibb, Millenium Pharmaceuticals, Gilead, Sanofi, Amgen, and Precision Biosciences; and is a scientific founder of C4 therapeutics and Oncopep. CJ reports research grants from Takeda; and honoraria from Takeda, Janssen, Celgene, and Amgen. HE reports research grants from Celgene, Janssen, Amgen, Sanofi, and GlaxoSmithKline; and honoraria from Celgene, Janssen, Amgen, Takeda, Sanofi, and GlaxoSmithKline. PS reports research grants from Amgen, Celgene, Janssen, Karyopharm, SkylineDX, and Takeda; and honoraria from Amgen, Celgene, Janssen, Karyopharm, SkylineDX, and Takeda. ME reports research grants from Amgen, Janssen, Takeda, and Bristol-Myers Squibb. RF reports being a consultant for Merck Sharp and Dohme, Novartis, Oncotracker, Pharmacyclics, GlaxoSmithKline, Janssen, Sanofi, Takeda, and Oncopeptides; and has a FISH patent with royalties paid. KW reports research grants from Amgen, Celgene, Janssen, and Sanofi; and honoraria from Amgen, Celgene, Bristol-Myers Squibb, Adaptive Biotech, Janssen, GlaxoSmithKline, Karyopharm, Sanofi, Takeda, and Oncopeptides. RB reports research grants from Janssen, Bristol-Myers Squibb, Karyopharm, Sanofi, and AbbVie; and honoraria from Janssen, Celgene, Karyopharm, Sanofi, and GlaxoSmithKline. VH reports honoraria from AbbVie, Amgen, Bristol-Myers Squibb, Janssen, Sanofi, and Takeda. JGB reports research grants from Vivolux, AbbVie, Amgen, Acetylon, Bluebird, Bristol-Myers Squibb, Celgene, Cellularity, Constellation, CRISPR Therapeutics, CURIS, EMD Sorono, GenentechInc, Glenmark, Janssen, Kesios, Lilly, Novartis, Poseida, Teva, and Takeda; and being a consultant for Amgen, Bioclinica, Bristol-Myers Squibb, Celgene, CRISPR Therapeutics, Janssen, Karyopharm, Kite Pharma, Legend, Prothena, Servier, Takeda, Bluebird, and SecuraBio. FLdC reports honoraria from Amgen, Takeda, Janssen, Viforpharma, and Celgene. AM reports honoraria from Janssen, Takeda, Amgen, Bristol-Myers Squibb, and Sanofi. AW reports research grants from Takeda and honoraria from Janssen. DHV reports honoraria from Amgen, Takeda, Janssen, GlaxoSmithKline, Karyopharm, and Bristol-Myers Squibb. EMO reports honoraria from Celgene, Janssen, Sanofi, Amgen, Merck Sharp and Dohme, Asofarma, Takeda, SecuraBio, Oncopeptides, and GlaxoSmithKline. HQ reports research grants from GlaxoSmithKline, Amgen, Karyopharm, and Celgene; and honoraria from GlaxoSmithKline, Amgen, and Karyopharm. JB reports honoraria from Janssen, Celgene, Amgen, Takeda, and Oncopeptides. PLB reports honoraria from Celgene, Janssen, GlaxoSmithKline, and Novartis. JH reports research grants from the National Natural Science Foundation of China and honoraria from Janssen. U-HM reports honoraria from Janssen, Sanofi, Amgen, Celgene, and Oncopeptides. DD reports research grants from Celgene and Janssen; and honoraria from Amgen, Celgene, Janssen, and Takeda. J-LH reports honoraria from GlaxoSmithKline, Daichi, and Janssen. HG reports research grants from Bristol-Myers Squibb, Celgene, Janssen, Chugai, Sanofi, Takeda, Novartis, Incyte, Molecular Partners, Mundipharma, and Adaptive Technologies; and honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Chugai, Sanofi, Novartis, and GlaxoSmithKline. NCM reports honoraria from AbbVie, Adaptive, Amgen, BeiGene, Bristol-Myers Squibb, Celgene, Janssen, Karyopharm, Takeda, and Oncopep. FG reports honoraria from Amgen, Celgene, Janssen, Takeda, Bristol-Myers Squibb, Roche, AbbVie, Adaptive Biotechnologies, Seattle Genetics, Oncopeptides, and GlaxoSmithKline. MBe reports participation in advisory boards for Amgen, Bristol-Myers Squibb, Janssen, Sanofi, Takeda, and Oncopeptides. LJC reports research grants from Amgen and Janssen; and honoraria from Amgen, Janssen, Genentech, AstraZeneca, and Bristol-Myers Squibb. MK reports research grants from Janssen and honoraria from Amgen, AbbVie, Celgene, GlaxoSmithKline, Janssen, Karyopharm, and Takeda. PH reports research grants from Celgene, Takeda, Janssen, GlaxoSmithKline, and Sanofi; and honoraria from Celgene, Takeda, Amgen, Karyopharm, Janssen, GlaxoSmithKline, and Sanofi. MBo reports research grants from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and Mundipharma; and honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, AbbVie, and GlaxoSmithKline. SZU reports research grants from Amgen, Bristol-Myers Squibb, Celgene, Pharmacyclics, Sanofi, Seattle Genetics, Janssen, Takeda, SkylineDX, and Merck Sharp and Dohme; and honoraria from Amgen, AbbVie, Celgene, Mundipharma, Sanofi, Seattle Genetics, Janssen, Takeda, SkylineDX, and Merck Sharp and Dohme. SZ reports research grants from Janssen and Takeda; and being a consultant for Janssen, Takeda, Bristol-Myers Squibb, Sanofi, and Oncopeptides. SHo reports research grants from Oncopeptides; and honoraria from Celgene, GlaxoSmithKline, Oncopeptides, Sorrento, Sanofi, Genentech, and Takeda. SHa reports research grants from Bristol-Myers Squib, Celgene, Janssen, and Amgen; and honoraria from Bristol-Myers Squib, Celgene, Janssen, Amgen, Takeda, GlaxoSmithKline, AbbVie, and Karyopharm. GC reports research grants from Takeda, Celgene, and Janssen; and honoraria from Takeda, Celgene, Janssen, and Karyopharm. M-VM reports honoraria from Janssen, Bristol-Myers Squib, Amgen, Takeda, GlaxoSmithKline, AbbVie, Adaptive, Pfizer, Genentech, Roche, Oncopeptides, and Sanofi. MAD reports honoraria from Amgen, Bristol-Myers Squib, Janssen, Takeda, and Beigene. PGR reports research grants from Bristol-Myers Squib, Oncopeptides, Celgene, Takeda; and honoraria from Oncopeptides, Celgene, Takeda, Karyopharm, Janssen, Sanofi, and SecuraBio. All other authors declare no competing interests. Publisher Copyright: © 2021 Elsevier Ltd

PY - 2021/3

Y1 - 2021/3

N2 - This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes.

AB - This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes.

UR - https://www.scopus.com/pages/publications/85101689680

U2 - 10.1016/S1470-2045(20)30756-7

DO - 10.1016/S1470-2045(20)30756-7

M3 - Article

SN - 1470-2045

VL - 22

SP - e105-e118

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 3

ER -

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Abstract

Bibliographical note

Research programs

Access to Document

Other files and links

Fingerprint

Cite this